Human recombinant activated protein C for severe sepsis (Q24243896)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1 reference

title

Human recombinant activated protein C for severe sepsis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

A Martí-Carvajal

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

A F Cardona

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

18 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

CD004388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

Impact of covert duplicate publication on meta-analysis: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Different patterns of duplicate publication: an analysis of articles used in systematic reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Recombinant human activated protein C for severe sepsis in neonates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Multiple publication of reports of drug trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Antibiotics in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Organ dysfunction during sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Historical perspective of the word "sepsis".

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Vioxx: an unequal partnership between safety and efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

1 reference

7 January 2021

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

1 reference

7 January 2021

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Financial relationships between institutional review board members and industry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Risks and benefits of activated protein C treatment for severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin alfa (activated) treatment of older patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Recombinant human activated protein C in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Applying patient selection criteria for drotrecogin alfa therapy in practice.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Recombinant human activated protein C in sepsis: assessing its clinical use.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

The protein C pathway

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Epidemiology of sepsis: an update

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin Alfa (Activated) Administration: Too Many Subgroups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Substantiating the concerns about recombinant human activated protein C use in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

The sirens are singing: The perils of trusting trials stopped early and subgroup analyses*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Prescribing indications based on successful clinical trials in sepsis: a difficult exercise

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Activated protein C (Xigris) treatment in sepsis: a drug in trouble

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

A definite role for treatment with activated protein C in sepsis? Standard use is premature

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Treatment of sepsis with activated protein C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Lessons from the withdrawal of rofecoxib

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Users' guide to detecting misleading claims in clinical research reports

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Science review: role of coagulation protease cascades in sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Critical advances in septicemia and septic shock

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

New and emerging therapies for sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Implications of pharmaceutical industry funding on clinical research.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Evidence-based medicine in the ICU: important advances and limitations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Excess in the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004388.PUB2

7 January 2021

10.1002/14651858.CD004388.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636755%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference